A subsequent study used publicly available transcriptional profiling data to demonstrate that BRD4 inhibition modulates a previously validated HR defect gene signature [84], though finding minimal impact on BRCA1 or RAD51 expression in cell lines of multiple cancer types. The gene discussed is BRD4; the disease is cancer.